← All trials
NCT05881668
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Apr 30, 2025
- First posted
- May 31, 2023
- Last posted
- Oct 12, 2023
- Enrollment
- 0
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversitySponsor investigator
- Sun Yat-Sen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.